Nabumetone is an anti-inflammatory drug (NSAID) for the treatment of pain and inflammation associated with rheumatoid arthritis and osteoarthritis. The incidence of gastrointestinal ulcers associated with nabumetone appears to be lower than for other NSAIDs, suggesting that the drug May be a preferential inhibitor of cyclooxygenase-2. Because the drug exhibits poor aqueous solubility, the researchers tried to improve the solubility by using various techniques . Efforts were also made to encourage rapid development of the therapeutic efficacy of the formulation as effervescent chewable tablet and a compressed annular tablet with molded triturate tablet .
Although the widely accepted conventional oral solid dosage forms, pediatric, geriatric, and bedridden patients have difficulty swallowing. In addition, for poorly soluble drugs, dissolution of the drug from the tablet is the rate-limiting step in the process of drug absorption . Because the rate and extent of drug absorption is determined by the rate and extent of dissolution of tablets of drugs, drugs with low aqueous solubility because of the irregularity or incomplete absorption from the gastrointestinal tract intestinal tract are known to pose potential bioavailability.
Because Nabumetone is practically insoluble in water, absorption will be dependent on the dissolution rate. This study attempts to resolve this problem through the formulation of the drug complexed with previously?-Cyclodextrin (?-CD) as quickly disperse porous tablet. These tablets are designed to disappear quickly and completely to facilitate complete dissolution of drug absorption after oral administration. Inclusion complexes were successfully used to improve solubility, dissolution and bioavailability of poorly soluble drugs .
No comments:
Post a Comment